Week in review: Luxturna, Novartis, NIDEK
- Posted on: Sep 28 2018
- Leave a response
This week, Luxturna approaches EU approval, Novartis’ brolucizumab outperforms aflibercept in neovascular AMD trials and NIDEK unveils a “groundbreaking” gonioscopy device that performs 360-degree iridocorneal angle imaging in full color.
Source: AAO
Posted in: Uncategorized
